SLC28A3 rs36084364: What Your Genotype Means
The genetic variant rs36084364 is a single nucleotide polymorphism located in the promoter region of the SLC28A3 gene. Research suggests this variant may influence the expression of the SLC28A3 transporter, potentially impacting an individual's risk of developing anthracycline-induced cardiotoxicity.
What each genotype means
Increased protection against cardiotoxicity
This genotype is associated with a reduced risk of developing anthracycline-induced cardiotoxicity compared to other genotypes. Research suggests this variant may influence the expression of the SLC28A3 transporter, which plays a role in how heart cells handle these medications. Please discuss your treatment plan and potential risks with your oncologist or pharmacist.
This genotype is found in a significant portion of the population, with the minor allele frequency for this variant typically ranging between 0.20 and 0.35 globally.
Intermediate protection profile
Carrying one copy of each allele suggests an intermediate influence on the expression of the SLC28A3 transporter. While some studies indicate a protective effect against anthracycline-induced heart damage, the clinical impact can be variable. You should consult with your healthcare provider to understand how this genetic information might be considered alongside other clinical factors during your treatment.
This heterozygous genotype is common, occurring in a substantial percentage of individuals across diverse ancestral backgrounds.
Baseline risk profile
This genotype represents the more common genetic state at this position and is generally considered the baseline for assessing anthracycline-induced cardiotoxicity risk. It does not provide the specific protective association observed with the alternative allele. Always discuss your medication safety and monitoring needs with your clinical team.
This is the most frequent genotype observed in most global populations.
Understanding rs36084364 and its Gene
The genetic variant rs36084364 is a single nucleotide polymorphism (SNP), a common type of genetic variation where a single base differs in the DNA sequence. This particular SNP is situated in the promoter region of the SLC28A3 gene. Promoter regions are crucial DNA sequences located near genes that regulate the rate of gene transcription, essentially acting as a switch to turn genes on or off, or to control how strongly they are expressed. Therefore, variants in a promoter region, like rs36084364, have the potential to alter the amount of protein a gene produces. The SLC28A3 gene, also known as hCNT3, encodes a transporter protein responsible for moving various organic cations, including certain drugs, across cell membranes.
The Link to Drug Response: Anthracyclines and Cardiotoxicity
Research has focused on rs36084364 due to its potential role in pharmacogenomics, the study of how genes affect a person's response to drugs. Specifically, this variant has been investigated for its association with cardiotoxicity, a serious side effect of anthracycline chemotherapy drugs, such as doxorubicin and daunorubicin. These drugs are widely used to treat various cancers. Studies have observed that individuals carrying certain genotypes of rs36084364 may have a reduced risk of developing heart damage when treated with these medications. The proposed mechanism involves the variant potentially reducing the expression of the SLC28A3 transporter, which may affect the uptake or efflux of anthracyclines within heart cells, thereby offering a protective effect against toxicity.
Strength of Evidence and Population Frequencies
The evidence linking rs36084364 to a protective effect against anthracycline-induced cardiotoxicity is currently classified as limited. While some studies have shown a statistically significant association, further research with larger and more diverse populations is needed to confirm these findings and fully understand the clinical implications. Regarding its prevalence, the minor allele of rs36084364 is present in approximately 20-35% of global populations. This suggests that the variant is relatively common, and different genotypes will be encountered across various ethnic groups, though frequencies can vary. Continued research and data collection from large-scale genomic databases like gnomAD are essential for a more precise understanding of its distribution.
What You Can and Cannot Do with This Information
Understanding your genotype for rs36084364 can provide insights into a potential predisposition regarding anthracycline chemotherapy. If you are a patient undergoing or considering treatment with anthracyclines, this information might be a starting point for a conversation with your healthcare provider. However, it is crucial to understand that this is not a diagnostic tool. Genetic predispositions do not guarantee an outcome, and many factors influence drug response and toxicity. For any questions about medication, including dosage and potential side effects, always consult your doctor or a qualified pharmacist. They can interpret your genetic information in the context of your overall health and medical history.
How common is this variant?
The minor allele of rs36084364 exhibits a minor allele frequency of approximately 0.20 to 0.35 across various global populations. This indicates that the variant is relatively common.
Frequently asked questions
What is rs36084364?
rs36084364 is a common genetic variation, a single nucleotide polymorphism (SNP), located in the promoter region of the SLC28A3 gene. It is believed to influence how strongly the SLC28A3 gene is expressed.
How does rs36084364 relate to cancer treatment?
This variant has been studied in relation to cardiotoxicity, a side effect of anthracycline chemotherapy drugs used to treat cancer. Some research suggests that certain genotypes of rs36084364 may provide a protective effect against this heart damage.
Is rs36084364 a definitive predictor of cardiotoxicity?
No, the evidence linking rs36084364 to cardiotoxicity is currently limited. Genetic factors are just one piece of the puzzle, and many other factors influence drug response and side effects.
Should I get tested for rs36084364 if I'm getting chemotherapy?
Discussing any genetic information, including potential variants like rs36084364, with your oncologist or pharmacist is recommended. They can integrate this information with your overall health profile to make informed treatment decisions.
How common is rs36084364 in different populations?
The minor allele for rs36084364 is relatively common globally, found in about 20-35% of individuals. However, the exact frequency can differ among various ancestral populations.
Sources & further reading
Educational information only, last refreshed 9/25/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs36084364?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29